Search results for "Autoimmunity"

showing 10 items of 349 documents

Ranking the impact of human health disorders on gut metabolism: Systemic lupus erythematosus and obesity as study cases

2015

Multiple factors have been shown to alter intestinal microbial diversity. It remains to be seen, however, how multiple collective pressures impact the activity in the gut environment and which, if any, is positioned as a dominant driving factor determining the final metabolic outcomes. Here, we describe the results of a metabolome-wide scan of gut microbiota in 18 subjects with systemic lupus erythematosus (SLE) and 17 healthy control subjects and demonstrate a statistically significant difference (p < 0.05) between the two groups. Healthy controls could be categorized (p < 0.05) based on their body mass index (BMI), whereas individuals with SLE could not. We discuss the prevalence of SLE c…

AdultAutoimmunityGut floramedicine.disease_causeArticleAutoimmunityBody Mass IndexmedicineHomeostasisHumansLupus Erythematosus SystemicMetabolomicsClinical significanceMicrobiomeObesityMultidisciplinaryLupus erythematosusbiologyMicrobiotaCase-control studyMiddle Agedmedicine.diseasebiology.organism_classificationObesityN-Acetylneuraminic AcidGastrointestinal TractCase-Control StudiesImmunologyMetabolomeFemaleMicrobiomeBody mass indexMetabolic Networks and PathwaysScientific Reports
researchProduct

Autoreactive CD4+ LKM-specific and anticlonotypic T-cell responses in LKM-1 antibody-positive autoimmune hepatitis

1996

Peripheral blood mononuclear cells (PBMC) of patients with autoimmune hepatitis (AIH) and controls were studied for their proliferative response to six overlapping synthetic peptides covering the 33-amino acid immunodominant region of cytochrome P450IID6, the main target antigen of LKM-1 antibody-positive type II AIH. PBMC from 8 of 8 type II AIH patients (100%), 6 of 12 LKM-1 antibody-negative type I AIH patients (50%), but only 4 of 31 patients with chronic hepatitis C (12.9%) reacted with a 23-amino acid LKM peptide and mainly with a shorter 18-amino acid LKM peptide. Follow-up showed that LKM-specific T-cell responses decreased after immunosuppression had started. Fine specificity, HLA …

AdultCD4-Positive T-LymphocytesMaleAdolescentT-LymphocytesT cellMolecular Sequence DataAutoimmune hepatitisLymphocyte Activationmedicine.disease_causeEpitopeAutoimmune DiseasesHepatitisImmunophenotypingAutoimmunityImmunophenotypingImmune systemMicrosomesmedicineHumansInterferon gammaAmino Acid SequenceCells CulturedAgedAutoantibodiesHLA-D AntigensHepatologybiologyAntibodies MonoclonalMiddle Agedmedicine.diseasePeptide Fragmentsmedicine.anatomical_structureImmunologybiology.proteinCytokinesFemaleAntibodymedicine.drugHepatology
researchProduct

Dimethyl fumarate treatment restrains the antioxidative capacity of T cells to control autoimmunity

2021

Abstract Dimethyl fumarate, an approved treatment for relapsing-remitting multiple sclerosis, exerts pleiotropic effects on immune cells as well as CNS resident cells. Here, we show that dimethyl fumarate exerts a profound alteration of the metabolic profile of human CD4+ as well as CD8+ T cells and restricts their antioxidative capacities by decreasing intracellular levels of the reactive oxygen species scavenger glutathione. This causes an increase in mitochondrial reactive oxygen species levels accompanied by an enhanced mitochondrial stress response, ultimately leading to impaired mitochondrial function. Enhanced mitochondrial reactive oxygen species levels not only result in enhanced T…

AdultCD4-Positive T-LymphocytesMaleDimethyl FumarateT cellAutoimmunityCD8-Positive T-Lymphocytesmedicine.disease_causeAntioxidantsCohort StudiesMiceYoung Adultchemistry.chemical_compoundMultiple Sclerosis Relapsing-RemittingImmune systemmedicineAnimalsHumanschemistry.chemical_classificationReactive oxygen speciesDimethyl fumarateExperimental autoimmune encephalomyelitisGlutathioneMiddle Agedmedicine.diseaseCell biologyMice Inbred C57BLmedicine.anatomical_structurechemistryFemaleNeurology (clinical)Immunosuppressive AgentsOxidative stressCD8Brain
researchProduct

Cellular and humoral immunity to the 60-kD heat shock protein in inflammatory bowel disease.

1997

Background: Mycobacteria have been considered a possible etiological agent in Crohn’s disease. Since cross-reactivity between epitopes of mycobacterial and self-heat shock protein might represent a potential disease mechanism, we determined the cellular and humoral immune responses to the mycobacterial and the human 60-kD heat shock protein, as well as various control antigens. Methods: We studied samples from 19 patients with Crohn’s disease, 12 patients with ulcerative colitis, and from 19 healthy individuals. T cell responses were studied using a standard proliferation assays to purified recombinant mycobacterial and human 60-kD heat shock protein. Antibody levels were measured by establ…

AdultCellular immunityEnzyme-Linked Immunosorbent AssayBiologymedicine.disease_causeLymphocyte ActivationInflammatory bowel diseaseMicrobiologyAutoimmunityImmune systemAntigenCrohn DiseaseHeat shock proteinmedicineHumansLymphocytesAntigens BacterialGastroenterologyChaperonin 60Mycobacterium tuberculosismedicine.diseaseShock (circulatory)Case-Control StudiesHumoral immunityImmunologyAntibody FormationColitis Ulcerativemedicine.symptomDigestion
researchProduct

Autoimmune Diabetes Recurrence After Pancreas Transplantation: Diagnosis, Management, and Literature Review

2019

[EN] Background: Pancreas transplantation can be a viable treatment option for patients with type 1 diabetes mellitus (T1DM), especially for those who are candidates for kidney transplantation. T1DM may rarely recur after pancreas transplantation, causing the loss of pancreatic graft. The aim of this study was to describe the prevalence of T1DM recurrence after pancreas transplantation in our series. Material/Methods: Eighty-one patients transplanted from 2002 to 2015 were included. Autoantibody testing (GADA and IA-2) was performed before pancreas transplantation and during the follow-up. Results: The series includes 48 males and 33 females, mean age 37.4+5.7 years and mean duration of dia…

AdultGraft RejectionMaleReoperationmedicine.medical_specialtyendocrine system diseasesmedicine.medical_treatment030232 urology & nephrologyAutoimmunity030230 surgeryPancreas transplantationGastroenterologyTECNOLOGIA ELECTRONICA03 medical and health sciences0302 clinical medicineRecurrenceDiabetes mellitusInternal medicinemedicineHumansProspective StudiesKidney transplantationAutoantibodiesOriginal PaperTransplantationType 1 diabetesGlutamate Decarboxylasebusiness.industryPancreatic isletsnutritional and metabolic diseasesImmunosuppressionGeneral Medicinemedicine.diseaseKidney TransplantationTransplantationmedicine.anatomical_structuresurgical procedures operativeDiabetes Mellitus Type 1FemalePancreas TransplantationPancreasbusinessImmunosuppression
researchProduct

Liver cirrhosis associated with heterozygous alpha-1-antitrypsin deficiency type Pi MS and autoimmune features.

1995

Patients with homozygous protease inhibitor (Pi) type ZZ or a few rare M-like types may develop liver cirrhosis due to intracellular storage of alpha-antitrypsin (AAT), whereas some patients with heterozygous Pi MZ or SZ normally present with transient abnormal liver function tests in childhood. We report a 42-year-old obese patient who developed liver cirrhosis in association with heterozygous Pi MS (AAT) deficiency. Immunohistological and electron microscope examination showed storage of AAT in the hepatocytes. Interestingly, autoimmune features in this patient suggest that abnormal immune responses may contribute to the pathology of chronic liver disease.

AdultLiver CirrhosisMalecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyHeterozygoteCirrhosisT-LymphocytesAlpha (ethology)medicine.disease_causeAutoimmunityAutoimmune DiseasesImmunoenzyme TechniquesInternal medicinealpha 1-Antitrypsin DeficiencyPiMedicineHumansProtease inhibitor (pharmacology)ObesityAutoimmune diseaseAlpha 1-antitrypsin deficiencybusiness.industryGastroenterologymedicine.diseaseTrypsin deficiencyFlow CytometryAlcoholismMicroscopy ElectronEndocrinologyPhenotypeLiveralpha 1-AntitrypsinCytokinesbusinessDigestion
researchProduct

Guinea pig transglutaminase immunolinked assay does not predict coeliac disease in patients with chronic liver disease

2001

BACKGROUND—It has been suggested that serological screening for coeliac disease (CD) should be performed in patients with chronic unexplained hypertransaminasaemia.
AIMS—To evaluate the specificity for CD diagnosis of serum IgA antitissue transglutaminase (tTG) determination in consecutive patients with chronic hypertransaminasaemia using the most widely utilised ELISA based on tTG from guinea pig as the antigen.
PATIENTS AND METHODS—We studied 98 patients with chronic hypertransaminasaemia, evaluated for the first time in a hepatology clinic. Serum anti-tTG and antiendomysial (EmA) assays were performed. Patients positive for EmA and/or anti-tTG were proposed for intestinal biopsy. Finally…

AdultLiver CirrhosisMalemedicine.medical_specialtySettore MED/09 - Medicina InternaCirrhosisAdolescentHepatitis Viral HumanTissue transglutaminaseGuinea PigsAutoimmunityEnzyme-Linked Immunosorbent AssayChronic liver diseaseSensitivity and SpecificityCoeliac diseaseArticleStatistics NonparametricAntiendomysial antibodieIntestinal histologySerologyLiver diseaseIntestinal mucosaPredictive Value of TestsInternal medicinemedicineAnimalsHumansFalse Positive ReactionsTransaminasesAutoantibodiesTransglutaminasesCoeliac diseasebiologybusiness.industryAntitissue transglutaminase antibodieGastroenterologyHepatologyMiddle Agedmedicine.diseaseImmunoglobulin ACeliac DiseaseImmunologyChronic Diseasebiology.proteinLinear ModelsFemalebusinessLiver disease
researchProduct

Hematological immune related adverse events after treatment with immune checkpoint inhibitors

2021

Abstract Introduction With the increasing use of checkpoint inhibitors, rare immune-related adverse events (irAE) are being identified. Haematological irAE (hem-irAE) are difficult to treat and have shown high mortality rates. In order to improve side-effect management for these potentially life-threatening events, we analysed frequency, severity and outcomes. Patients and methods Patients who developed hem-irAE while being treated with immune checkpoint inhibitors (ICI) therapy were retrospectively identified from 18 international cancer centres. Results In total, more than 7626 patients treated with ICI were screened, and 50 patients with hem-irAE identified. The calculated incidence amou…

AdultMale0301 basic medicineCancer Researchmedicine.medical_specialtyNeutropeniamedicine.medical_treatmentMedizinNeutropeniamedicine.disease_causeGastroenterologyAutoimmunityYoung Adult03 medical and health sciences0302 clinical medicineImmune systemAdrenal Cortex HormonesInternal medicinemedicineHumansAdverse effectImmune Checkpoint InhibitorsAgedRetrospective StudiesAged 80 and overHemophagocytic lymphohistiocytosisbusiness.industryIncidenceIncidence (epidemiology)CancerAnemiaImmunosuppressionMiddle Agedmedicine.diseaseThrombocytopeniaTreatment Outcome030104 developmental biologyOncology030220 oncology & carcinogenesisFemalebusinessImmunosuppressive Agents
researchProduct

Blood coagulation factor XII drives adaptive immunity during neuroinflammation via CD87-mediated modulation of dendritic cells

2016

Aberrant immune responses represent the underlying cause of central nervous system (CNS) autoimmunity, including multiple sclerosis (MS). Recent evidence implicated the crosstalk between coagulation and immunity in CNS autoimmunity. Here we identify coagulation factor XII (FXII), the initiator of the intrinsic coagulation cascade and the kallikrein–kinin system, as a specific immune cell modulator. High levels of FXII activity are present in the plasma of MS patients during relapse. Deficiency or pharmacologic blockade of FXII renders mice less susceptible to experimental autoimmune encephalomyelitis (a model of MS) and is accompanied by reduced numbers of interleukin-17A-producing T cells.…

AdultMale0301 basic medicineEncephalomyelitis Autoimmune ExperimentalMultiple Sclerosisanimal structuresT-LymphocytesScienceMedizinGeneral Physics and AstronomyKininsCoagulation Factor XIIAdaptive ImmunityBiologymedicine.disease_causeArticleGeneral Biochemistry Genetics and Molecular BiologyReceptors Urokinase Plasminogen ActivatorAutoimmunityYoung Adult03 medical and health sciencesImmune systemddc:570medicineAnimalsHumansddc:610cardiovascular diseasesNeuroinflammationAgedFactor XIIMultidisciplinaryInterleukin-17QExperimental autoimmune encephalomyelitisCell DifferentiationDendritic CellsGeneral ChemistryMiddle Agedmedicine.diseaseAcquired immune systemMice Inbred C57BL030104 developmental biologyNeuroimmunologyFactor XIIImmunologyFemaleKallikreinscirculatory and respiratory physiologyNature Communications
researchProduct

Chromogranin Serves as Novel Biomarker of Endocrine and Gastric Autoimmunity

2020

Abstract Context The glycoprotein chromogranin A (CgA) is expressed by endocrine and neuroendocrine cells. High levels of serum CgA serve as markers of neuroendocrine tumors (NET), but its role in autoimmunity has not been assessed. Objective To investigate CgA utility as a marker of endocrine autoimmunity. Methods CgA serum levels were evaluated in 807 consecutive unselected participants (cross-sectional study) with the time-resolved amplified cryptate emission technology. Results Serum CgA concentrations were increased in 66%, 39%, 38%, and 24% of patients with NET, type 1 diabetes (T1D), autoimmune gastritis (AG) and autoimmune polyendocrinopathy (AP), respectively. Compared with healthy…

AdultMale0301 basic medicineendocrine systemmedicine.medical_specialtyAdolescentAutoimmune GastritisEndocrinology Diabetes and MetabolismClinical BiochemistryAutoimmunity030209 endocrinology & metabolismContext (language use)Neuroendocrine tumorsBiochemistryYoung Adult03 medical and health sciences0302 clinical medicineEndocrinologyPredictive Value of TestsInternal medicineGastrinsmedicineHumansPolyendocrinopathies AutoimmuneAgedAutoantibodiesType 1 diabetesbiologybusiness.industryBiochemistry (medical)AutoantibodyChromogranin AAutoimmune polyendocrinopathyMiddle Agedmedicine.diseaseHealthy VolunteersNeuroendocrine TumorsCross-Sectional StudiesDiabetes Mellitus Type 1030104 developmental biologyEndocrinologyROC CurveGastritisbiology.proteinChromogranin ABiomarker (medicine)FemalebusinessBiomarkersThe Journal of Clinical Endocrinology &amp; Metabolism
researchProduct